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Genistein and its biological activities
The isoflavone genistein (5,7,4'-trihydroxyisoflavone) (Figure 1 ) is present primarily in soybeans and a variety of legumes (Reinli and Block 1996) , where its content can differ depending on the variety of soybean, the year harvested, geographic location and plant part (Delmonte and Rader 2006) . Non-soy legumes such as lentils and other types of beans do not contain appreciable amounts of genistein (Liggins et al 2000) . However, genistein can also occur in soy products in the form of its glycoside ( Figure 1 ) genistin (Liggins et al 2000; Reinli and Block 1996) . Genistein exhibits a wide range of biological effects that contribute to its potential health benefits (Head 1998) , such as oestrogenic activity (Cassidy et al 1994) ,
anticancer effects (Messina and Bennink 1998) , antioxidant actions (Cai and Wei 1996) , and anti-inflammatory activity (Fanti et al 2006) .
Oestrogenic activity
Isoflavones are structurally similar to oestrogens (Miksicek 1995) and can function both as oestrogen agonists and antagonists depending on the hormonal milieu and the target tissue and species under investigation (Molteni et al 1995) . Genistein's anti-oestrogenic effects are due to its ability to bind to the oestrogen receptor (Wang et al 1996; Yearley et al 2007) , therefore suppressing the more harmful effects of oestrogens, such as their effects on oestrogen-sensitive cancers (Anthony et al 1998; Goodman et al 1997; Horn-Ross et al 2003) .
For example, in MCF-7 breast cancer cells, which are known to be estrogen receptor positive, genistein is able to stimulate estrogen-responsive pS2 mRNA expression and compete with
[3H]-estradiol binding to the estrogen receptor with 50% inhibition (Wang et al 1996) .
Furthermore, isoflavones have been found to exert an estrogenic effect in both the absence or presence of endogenous estrogen (Adlercreutz and Mazur 1997) . Alternatively, genistein may reduce oestrogenic activity via its ability to induce the production of sex hormone-binding globuline SHBG, thus leading to a faster clearance of sex hormones (including oestrogens) (Mousavi and Adlercreutz 1993 ) and a reduced risk of hormone-sensitive breast and prostate cancer (Messina and Hilakivi-Clarke 2009; Smith et al 2008) . Similarly, genistein is known to inhibit many of the enzymes involved in the biosynthesis and metabolism of steroid hormones (Head 1998) . For example, genistein has direct effects on cellular progesterone synthesis which involve the inhibition of hydroxysteroid dehydrogenase/isomerase (3beta-HSD) enzyme activity across the post-cyclic AMP pathway. It directly affects cellular progesterone synthesis through its inhibition of 3beta-HSD gene expression and down-regulation of its transcription (Tiemann et al 2007) .
There is convincing evidence that a diet rich in soy-protein, which contains genistein, has an impact on the hormonal status and the regulation of the menstrual cycle of premenopausal women (Cassidy et al 1994) . A daily intake of 60g of soy protein (containing 45 mg isoflavones)
for 1 month significantly increased follicular phase length and/or delayed menstruation, significantly suppressed the mid-cycle surges of luteinizing hormone and follicle-stimulating hormone and increased plasma estradiol concentrations in the follicular phase (Cassidy et al 1994) . These effects were potentially associated with lower risk of breast cancer (Cassidy et al 1994; Henderson et al 1985) .
Anticancer effects
Interest in genistein as a anticancer agent arose due to population-based data indicating a link between genistein consumption and a decreased risk of mortality from several types of cancer, in particular prostate and breast cancer (Pavese et al 2010) . Epidemiological studies indicate a protective effect of isoflavone ingestion against breast cancer in premenopausal women and women who had high soy intakes during adolescence (Peeters et al 2003; Piller et al 2006) , whereas in postmenopausal women the data vary depending on the study (Jones et al 2002; Ju et al 2006; Ju et al 2002) . Genistein is a potent inhibitor of the growth of breast cancer cells, whereas its beta-glucoside genistin has little effect Barnes 1991, 1993) .
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The effects of genistein on breast cancer cell growth and proliferation were studied in estrogen-receptor negative (MDA-468) and positive (MCF-7 and MCF-7-D-40) cell lines and it was ascertained that the presence of the estrogen receptor is not required for genistein to inhibit the cancer cell growth (Peterson and Barnes 1991) . The estrogen-independent effects of genistein can be due to their ability, or the ability of one of their metabolites, to block cell cycle progression through direct effects on intracellular signalling (Nguyen et al 2006) . For example, genestein has been shown to be capable of causing a cell cycle block in the G2/M phase in vitro (Cappelletti et al 2000; Santell et al 2000) and an overexpression of cyclin dependent kinase inhibitor p21WAF1 in breast cancer cells, leading to cell cycle arrest (Chinni et al 2003) . Other mechanisms whereby genistein can exert its anticancer properties include induction of apoptosis (Sergeev 2004; Xu and Loo 2001) , inhibition of tyrosine kinases (Mitropoulou et al 2002; Morton et al 1999) , modulation of the MAPK kinase signalling (Li et al 2006) Another mechanism of increased prostate cancer cell death by genistein is proposed to occur via its ability to inhibit NF-kappaB signalling, leading to altered expression of regulatory cell cycle proteins such as cyclin B and/or p21WAF1/Cip1, thus promoting G2/M arrest. These findings support the important and novel strategy of combining genistein with radiation for the treatment of prostate cancer (Raffoul et al 2006) .
Antioxidant action
Genistein, similar to other isoflavones, possesses a relatively strong antioxidant potential in vitro (Han et al 2009) , and exerts its antioxidant actions by scavenging free radicals ( , and by enhancing the activity of endogenous antioxidant enzymatic systems, such as catalase (Cai and Wei 1996) . Whilst direct antioxidant actions in vivo are highly unlikely (Williams et al 2004) , at physiologically achievable concentrations of 5 nM genistein increased intracellular-reduced glutathione (GSH) levels by approximately 10 %, whereas cellular alpha-tocopherol and uric acid remained unchanged (Guo et al 2002) . The mechanisms behind increases in GSH may include the effect of isoflavones on enzymes involved in the synthesis of GSH such as γ-GCS (Guo et al 2002) . Dietary administration of genistein for 30 days in mice increases the activity of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase and glutathione in various organs, including skin, small intestine, liver, kidney, and lung (Cai and Wei 1996) . Furthermore , treatment of macrophages with genistein reduces LPS induced GSH depletion and induces superoxide dismutase (SOD) and catalase (Choi et al 2003) . Similar effects have been reported in rats, where feeding the animals with an isoflavone-rich diet increased glutathione peroxidase and glutathione reductase activities, blood glutathione levels and glutathione S-transferase levels in kidney (Appelt and Reicks 1999) .
Anti-inflammatory activity
Genistein has been shown to have an effect on the production of inflammatory mediators in human peripheral blood mononuclear and polymorphonuclear leukocytes stimulated with lipopolysaccharide (LPS) and interferon-gamma (IFN(gamma) (Richard et al 2005) .
Genistein's anti-inflammatory activity has also been noted in human brain microvascular endothelial cells, where it dose-dependently inhibited cytokine-induced up-regulation of proinflammatory mediators such as tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), and intercellular adhesion molecule-1 (ICAM-1) and cytokine-induced transmigration of blood leukocytes (Lee and Lee 2008) . Exposure to high amounts of genistein, as occurs in traditional East Asian diets, where the mean total intake of isoflavones is estimated between 17 and 47 mg/day (Vergne et al 2009) , may be associated with a lower incidence of inflammatory bowel disease (IBD) (Loftus 2004) . Indeed, the risk of IBD appears to increase in Asian immigrants adopting western lifestyles, suggesting a protective role for isoflavones (Loftus 2004) . To confirm this hypothesis, the effect of orally administered genistein on the inflammatory response to 2,4,6-trinitrobenzenesulfonic acid-induced chronic colitis in rats has been investigated and indicates that genistein exerts beneficial anti-inflammatory effects by inhibiting molecular and biochemical inflammatory markers in the colon, specifically cyclooxygenase-2 (COX-2) and myeloperoxidase (MPO) (Seibel et al 2009) . Diabetic retinopathy (DR) is also associated with microglial activation and increased levels of inflammatory cytokines and the efficacy of genistein for alleviation of diabetes-induced retinal inflammation has been studied in an animal model of diabetes. Genistein was found to be effective in dampening diabetes-induced retinal inflammation by reducing TNF-α release and inhibiting ERK and P38 phosphorylation in activated microglial cells (Ibrahim et al 2010) . and is subjected to significant intracellular metabolism by CYP450 enzymes leading to the formation of both 5,7,3',4'-tetrahydroxyisoflavone (THIF; orobol) and two glutathionyl conjugates of THIF (Nguyen et al 2006) . A scheme of the described metabolic pathways is presented in figure 2 . It iss also shown that the co-treatment with cimetidine prevents the conversion of genistein to THIF, and because cimetidine is known to inhibit the CYP450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4, it is likely that one of these isoenzymes is responsible for the conversion of genistein to THIF in T47D cells (Nguyen et al 2006) . Previously, it has been suggested that isoflavone metabolism in transformed but not non-transformed breast epithelial cells may modulate the growth inhibitory effects of genistein (Peterson et al 1996) .
Glutathionyl conjugates of THIF in cells may be formed either enzymatically via the action of glutathione S-transferase or non-enzymatically via oxidative metabolism of THIF and subsequent reaction of THIF o-quinone with the cellular thiol GSH. However, the inhibition of glutathione S-transferase does not block glutathione conjugate formation, indicating that the latter is more likely to occur (Nguyen et al 2006) . Conjugations with thiols, such as glutathione, represent a major target for quinones, and the detoxification of quinones by GSH conjugation is generally considered to be cytoprotective (Monks and Lau 1997) . Glutathionyl conjugates from a variety of polyphenol quinones have been observed in cellular systems and display a wide array of biological activities (Corona et al 2006; Monks and Lau 1997; Spencer et al 2003) . Indeed, the redox activity of polyphenols is frequently enhanced following conjugation with GSH (Monks and Lau 1997) and as GSH conjugation is often coupled to the subsequent export of the adduct from cells, the conjugation of THIF appears to represent a detoxification pathway (Monks and Lau 1997; Spencer et al 2003) .
5,7,3',4'-tetrahydroxyisoflavone (THIF) and cancer
The exposure of breast epithelial cells to physiological concentrations of genistein selectively induces growth arrest and G2-M phase cell cycle block in tumorigenic (T47D) but not nontumorigenic (MCF10A) breast epithelial cells (Nguyen et al 2006) . These effects of cancer cell proliferation were paralleled by significant differences in the association of genistein with cells and in particular its intracellular metabolism (Nguyen et al 2006) . Previously, it had been suggested that isoflavone metabolism in transformed but not non-transformed breast epithelial cells may modulate the growth inhibitory effects of genistein (Peterson et al 1996) . In agreement with this hypothesis, genistein appeared to be selectively taken up into tumorigenic breast epithelial cells and subjected to significant intracellular metabolism leading to the formation of THIF and two glutathionyl conjugates of THIF (Nguyen et al 2006) . In contrast, there was minimal cell-association of genistein with MCF10A cells and no subsequent formation of free THIF (Nguyen et al 2006) . In breast cancer cells THIF formation triggers the activation of the MAP kinase p38 (Figure 3 ). Active p38 prevents the phosphorylation of cyclin B1 and hence its transport to the nucleus, an event essential for correct functioning of the cdc2-cyclin B1 complex. In addition, active p38 may undergo translocation to the nucleus where it directly inhibits the phosphorylation/activation of cdc2, thereby blocking entry of cells into mitosis (G2-M block) (Nguyen et al 2006) . These data suggest that the formation of THIF is crucial in driving the anti-cancer effects of genistein in vivo, in particular by inhibiting the proliferation of cancer cells but not affecting normal cell function. Further evidence relating to the cellular actions of the genistein metabolite, THIF, were elucidated in human breast carcinoma cells and summarized in figure 3 (Vauzour et al 2007) . Here THIF induced a G2-M cell cycle arrest in T47D tumorigenic breast epithelial cells which was mediated by the activation of ataxia telangiectasia and Rad3-related kinase (ATR) via its phosphorylation at Ser 428 (Vauzour et al 2007) . This activation of ATR appeared to result from THIF-induced increases in intracellular oxidative stress, a depletion of cellular GSH and an increase in DNA strand breakage (Vauzour et al 2007) . These events led to the downstream inhibition of cdc2, which was accompanied by the phosphorylation of both p53 (Ser 
5,7,3',4'-tetrahydroxyisoflavone (THIF) and endothelial function
Genistein has been shown to be able to protect endothelial cells against damage induced by oxidative stress and decreases intracellular glutathione levels (Hernandez-Montes et al 2006).
These effects appear to also be mediated by genistein intracellular metabolism. When genistein enters cells it is subject the CYP450-induced intracellular metabolism yielding THIF.
THIF may also react with intracellular GSH to form the adduct THIF-GSH ( 
Summary
The cellular mechanism of action of genistein will be dependent on the cellular metabolism and uptake of the compound. Genistein enters the cells where it is hydroxylated to form 5,7,3',4'-tetrahydroxyisoflavone (THIF). It is suggested that THIF formation is crucial for its cellular activity and can be mediated by interactions of the newly formed cellular metabolite with signalling pathways. THIF is generated by the action of CYP450 enzymes in cells (Nguyen et al 2006) and the catechol group-containing metabolite is observed to persist within the cells for up to 24 h without undergoing O-methylation (Vauzour et al 2007) as has been observed for other catechol containing polyphenols (Corona et al 2006; Spencer et al 2003) .
Indeed cellular actions of isoflavones are cell-type specific and also depend on its P450-related metabolism, oxidative metabolism, and GSH-conjugation (Hernandez-Montes et al
2006). Experiments conducted by testing both genistein and daizein in endothelial cells
showed that only genistein significantly protected against the oxidative injury induced by hydrogen peroxide whereas daizein had no protective effect. In the same cell line, both genistein and daidzein significantly increased γ-glutamylcysteine-synthetase levels and were able to induce increases in cytosolic accumulation and nuclear translocation of Nrf2. In contrast GSH levels increased only in the cells treated with daidzein; whereas with genistein, they were significantly lower, due to its sequestration by metabolism. In addition, cytosolic levels of Nrf1, and the degree to which Nrf1 underwent nuclear translocation, were significantly higher in cells exposed to genistein than in those exposed to daidzein. Therefore it appeared that protection by genistein depended on its induction of GPx and changes in Nrf1 activation, suggesting that they may underlie its protective effects in endothelial cells, and be mediated by intracellular metabolism to THIF that is only relevant to genistein but not daidzein were hydroxylation cannot occur. Future work would be needed to fully investigate these metabolic difference in view of a more complete understanding on their molecular mechanism of action, and ascertain the presence of intracellular metabolites in plasma and urines following genistein intake. Genistein can also undergo metabolic conjugation to glucuronic acid or sulphuric acid in the intestinal epithelium and in the liver. Intracellularly, genistein is hydroxylated to 5,7,3',4'-tetrahydroxyisoflavone (THIF; orobol) and two glutathionyl conjugates of THIF can also be formed. where it is subject the CYP450-induced intracellular metabolism yielding THIF. THIF may also react with intracellular GSH to form the adduct THIF-GSH, inducing a reduction of intracellular GSH and an increased DNA damage. Genistein and THIF might induce the transcription of antioxidant enzymes: more specifically genistein directly activate the translocation of Nrf2, which will increase the transcription of γ-GCS, leading to increases in GSH synthesis, whereas THIF stimulates the release of Nrf1 with the subsequent translocation into the nucleus where it may interact with the electrophile response element and induce the transcription of GPx.
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THIF triggers the activation of the MAP kinase p38. Active p38 prevents the phosphorylation of cyclin B1 and hence its transport to the nucleus, an event essential for correct functioning of the cdc2-cyclin B1 complex. In addition, active p38 may undergo translocation to the nucleus where it directly inhibits the phosphorylation/activation of cdc2, thereby blocking entry of cells into mitosis (G2-M block).
THIF formation also induces the activation of ATR, accompanied by the phosphorylation of both p53 and Chk1, downstream signals playing an important role in DNA damage checkpoint control. One of p53 downstream targets is the tumour suppressor protein p21 Waf1/Cip1, which can act as an inhibitor of cell cycle progression via its ability to inhibit cdc2. THIFinduced activation of Chk1 is paralleled by an inactivation of cdc25C phosphatase, causing it to be sequestered it in the cytoplasm and preventing it from de-phosphorylating cdc2.
Summary points

•
The isoflavone genistein is present in soy products, mainly in the form of glycosides such as genistin.
• Genistein consumption is associated to numerous potential health benefits, such as estrogenic activity, anticancer effects, antioxidant actions, anti-inflammatory activity and cardiovascular effects.
• The biological effects of genistein in cells and tissues will be dependent on its absorption, metabolism and distribution.
• The most prevalent forms in the diet do not necessarily give rise to the highest concentrations in vivo and metabolites may be present in relevant amounts.
• Glycosilated forms of genistein are not absorbed intact in humans and their bioavailability requires hydrolysis to occur in the stomach and/or large intestine.
• Genistein can be absorbed by passive diffusion in the small intestine, or can be converted to dihydrogenistein and 6'-hydroxy-O demethylangolensin (DMA) in the colon.
• Genistein can undergo phase II metabolic conjugation to glucuronic acid or sulphuric acid, catalyzed by UDP-glucuronyl transferase or sulfotransferase enzymes in the intestinal epithelium and in the liver.
• Intracellularly, genistein is subjected to metabolic transformation by CYP450 enzymes leading to the formation of both 5,7,3',4'-tetrahydroxyisoflavone (THIF; orobol) and two glutathionyl conjugates of THIF.
• THIF formation is crucial for cellular activity, acts via a mechanism involving oxidative DNA oxidation and the activation of downstream signaling pathways, and may mediate the effects of genistein intracellularly.
Key facts of flavonoids metabolism
• The biological properties of flavonoids in the diet and their activity in vivo are dependent on the extent of their biotransformation and conjugation during absorption.
• The most prevalent flavonoids in the diet do not necessarily correspond to the most bioactive forms in vivo.
• Glycosylation has a great influence on flavonoid absorption and glycosilated forms may not be absorbed intact in humans.
• Dietary flavonoids are subjected to extensive phase I (oxidation, reduction, hydrolysis) and phase II (conjugation to glucuronic acid, sulfate, glutathione) metabolic reactions catalized by enzymes such as cytochrome P450 found both in the small intestine and the liver.
• Further transformations of flavonoids may occur in the colon, where bacterial enzymes may catalyse many reactions including hydrolysis, dehydroxylation, demethylation, ring cleavage and decarboxylation as well as rapid de-conjugation, and are also able to catalyse the breakdown of the flavonoid backbone itself to simpler molecules such as phenolic acids.
